Corvus Pharmaceuticals CRVS Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$15.28M+75.5% | -$62.29M-130% | -$27.03M+34.6% | -$41.31M+4.5% | ||
| $105K+23.5% | $85K-43.7% | $151K-58.9% | $367K-20.2% | ||
| $5.33M+77.5% | $3M+39.9% | $2.15M-20.2% | $2.69M-36.4% | ||
| —— | $5K— | —— | $22K— | ||
| —— | $1.06M— | —— | —— | ||
| $2.76M+1,227% | -$245K+93.3% | -$3.68M— | —— | ||
| -$338K-1,307% | $28K+103% | -$1.07M-9.8% | -$973K-447% | ||
| -$1.96M+38.8% | -$3.2M+39.5% | -$5.28M+47.2% | -$10.01M-107% | ||
| -$185K— | —— | -$1.23M-17.3% | -$1.05M— | ||
| $223K— | —— | -$40K+62.6% | -$107K— | ||
| -$32.8M-29.0% | -$25.42M-6.2% | -$23.94M+11.4% | -$27.02M+26.4% | ||
| $174K— | —— | —— | —— | ||
| $91.75M+30.8% | $70.12M+49.0% | $47.05M-28.9% | $66.19M+607% | ||
| $84.13M+97.3% | $42.63M-31.9% | $62.62M+45.1% | $43.16M+39.6% | ||
| —— | $5K— | —— | $22K— | ||
| —— | -$27.48M— | —— | —— | ||
| $684K-95.8% | $16.41M— | —— | —— | ||
| $36.43M— | —— | $7.86M— | $0-100% | ||
| —— | —— | -$539K+98.9% | -$50.3M— | ||
| $1.35M+17.9% | $1.14M+27.6% | $894K+426% | $170K— | ||
| -$1.96M+38.8% | -$3.2M+39.5% | -$5.28M+47.2% | -$10.01M— | ||
| $2.76M+1,227% | -$245K+93.3% | -$3.68M— | —— | ||
| -$185K— | —— | -$1.23M-17.3% | -$1.05M— | ||
| $223K— | —— | -$40K+62.6% | -$107K— | ||
| —— | $1.59M— | —— | -$581K— | ||
| $84.13M+97.3% | $42.63M-31.9% | $62.62M+45.1% | $43.16M+39.6% | ||
| —— | $5K— | —— | $22K— | ||
| —— | $33.38M— | —— | —— | ||
| -$185K— | —— | -$1.23M-17.3% | -$1.05M— | ||
| —— | $5.03M— | —— | —— | ||
| —— | $1.21M— | —— | —— | ||
| $1.77M-86.8% | $13.4M— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$32.97M— | —— | -$23.97M— | —— | ||
| -$32.97M— | —— | -$23.97M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Corvus Pharmaceuticals generate?
- Corvus Pharmaceuticals (CRVS) generated -$34.9M in operating cash flow over the trailing twelve months.
- What is Corvus Pharmaceuticals's free cash flow?
- After $229.0K of capital expenditures, Corvus Pharmaceuticals's free cash flow was -$35.1M over the trailing twelve months, down 45.7% year over year.
- Where does Corvus Pharmaceuticals's cash flow data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.